Soligenix Inc. - Asset Resilience Ratio
Soligenix Inc. (SNGX) has an Asset Resilience Ratio of 0.00% as of September 2018. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (1999–2017)
This chart shows how Soligenix Inc.'s Asset Resilience Ratio has changed over time. Check Soligenix Inc. strategic capital allocation to assess the company's strategic physical and investment asset allocation.
Liquid Assets Composition Over Time
This chart breaks down Soligenix Inc.'s liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see Soligenix Inc. stock valuation.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $0.00 | 0% |
| Total Liquid Assets | $0.00 | 0.00% |
Asset Resilience Insights
- Limited Liquidity: Soligenix Inc. maintains only 0.00% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company maintains a balanced mix of cash and short-term investments.
Soligenix Inc. Industry Peers by Asset Resilience Ratio
Compare Soligenix Inc.'s asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Ascendis Pharma AS
NASDAQ:ASND |
Biotechnology | 0.00% |
|
ALTEOGEN Inc
KQ:196170 |
Biotechnology | 55.57% |
|
Apogee Therapeutics, Inc. Common Stock
NASDAQ:APGE |
Biotechnology | 47.01% |
|
Definium Therapeutics, Inc.
NASDAQ:DFTX |
Biotechnology | 34.94% |
|
Neuren Pharmaceuticals Ltd
AU:NEU |
Biotechnology | 90.43% |
|
Galapagos N.V.
AS:GLPG |
Biotechnology | 86.45% |
|
Blue Jet Healthcare Limited
NSE:BLUEJET |
Biotechnology | 13.81% |
|
Inventiva S.A
PA:IVA |
Biotechnology | 52.73% |
Annual Asset Resilience Ratio for Soligenix Inc. (1999–2017)
The table below shows the annual Asset Resilience Ratio data for Soligenix Inc..
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2017-12-31 | 0.00% | $0.00 | $9.55 Million | -- |
| 2016-12-31 | 0.00% | $0.00 | $10.27 Million | -- |
| 2015-12-31 | 0.00% | $0.00 | $7.39 Million | -- |
| 2014-12-31 | 0.00% | $0.00 | $6.95 Million | -- |
| 2013-12-31 | 0.00% | $0.00 | $8.27 Million | -- |
| 2012-12-31 | 0.00% | $0.00 | $4.71 Million | -- |
| 2011-12-31 | 0.00% | $0.00 | $8.22 Million | -- |
| 2000-12-31 | 14.74% | $2.01 Million | $13.67 Million | -23.52pp |
| 1999-12-31 | 38.26% | $3.55 Million | $9.27 Million | -- |
About Soligenix Inc.
Soligenix, Inc., a late-stage biopharmaceutical company, focuses on the development and commercialization of products to treat rare diseases in the United States. It operates through two segments, Specialized BioTherapeutics and Public Health Solutions. The Specialized BioTherapeutics segment develops SGX301 (HyBryte), a photodynamic therapy, which has completed Phase 3 clinical trial for the tre… Read more